IJMABHR International Journal of Medical and All Body Health ResearchIJMABHR 2582-8940 Anfo Publication House 80 An overview on rare fungal infection “Mucormycosis” incited by covid-19 AgrawalAnkit JainSourabh SharmaShikha RathoreAbhimanyu S GuptaArun K Associate Professor, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India 2021 2 3 24 26 20072021 10082021 CC BY-NC-SA 4.0

India is now seeing in COVID-19-induced Mucormycosis or “black fungus” cases in many regions, despite still grappling with second wave of coronavirus infections. Mucormycosis, also known as black fungus, is a severe but rare fungal infection caused by the mucormycetes, a group of moulds. It usually affects those with health problems or who are taking drugs that limit the body’s ability to combat germs and illness. The resurgence in black fungus infections may be attributed to the use of steroids in the management of COVID infection, as well as the fact that many COVID patients had diabetes as co-morbidity. Despite its occurrence since the beginning of the pandemic, there are still unanswered concerns regarding the origin of this fungal infection. The existing report of black fungus morbidity during the latest COVID-19 crisis in this study is early detection of this potentially life-threatening illness and timely care was critical in lowering mortality rates.

 COVID-19MucormycosisBlack FungusAntifungal References Hejazi II, Beg MA, Imam MA, et al. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV- 2 main protease. Food Chem Toxicol. 2021; 150:112057. Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019; 5(1):26. Francis JR, Villanueva P, Bryant P, et al. Mucormycosis in Children: Review and Recommendations for Management. J Pediatric Infect Dis Soc. 2018; 7(2):159-164. Afroze SN, Korlepara R, Rao GV, et al. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. Contemp Clin Dent. 2017; 8(4):662-666. Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017; 17(1):283. Kanamori H, Rutala WA, Sickbert-Bennett EE, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015; 61(3):433-444. Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012; 54 (1):S16-S22. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012; 54 (1):S23-S34. Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y). 2012; 8(2):140-142. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009; 15(5):2–9. Al-Ajam MR, Bizri AR, Mokhbat J, et al. Mucormycosis in the Eastern Mediterranean: a seasonal disease. Epidemiol Infect. 2006; 134(2):341- 346. Ahmed A, Adelmann D, Fahal A, et al. Environmental occurrence of Madurella mycetomatis the major agent of human eumycetoma in Sudan. J Clin Microbiol. 2002; 40(3):1031-1036. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13(2):236-301.